Literature DB >> 20388788

The effect of CXCL12 processing on CD34+ cell migration in myeloproliferative neoplasms.

Sool Yeon Cho1, Mingjiang Xu, John Roboz, Min Lu, John Mascarenhas, Ronald Hoffman.   

Abstract

Primary myelofibrosis (PMF) and polycythemia vera (PV) are chronic myeloproliferative neoplasms. PMF and, to a lesser degree, PV are characterized by constitutive mobilization of hematopoietic stem cells (HSC) and progenitor cells (HPC) into the peripheral blood (PB). The interaction between the chemokine CXCL12 and its receptor CXCR4 plays a pivotal role in determining the trafficking of CD34(+) cells between the bone marrow (BM) and the PB. PMF, but not PV, is associated with downregulation of CXCR4 by CD34(+) cells due to epigenetic events. Both PV and PMF patients have elevated levels of immunoreactive forms of CXCL12 in the BM and PB. Using electrospray mass spectrometry, the PB and BM plasma of PV and PMF patients was shown to contain reduced amounts of intact CXCL12 but significant amounts of several truncated forms of CXCL12, which are lacking in normal PB and BM plasma. These truncated forms of CXCL12 are the product of the action of several serine proteases, including dipeptidyl peptidase-IV, neutrophil elastase, matrix metalloproteinase-2 (MMP-2), MMP-9, and cathepsin G. Unlike CXCL12, these truncates either lack the ability to act as a chemoattractant for CD34(+) cells and/or act as an antagonist to the action of CXCL12. These data suggest that proteolytic degradation of CXCL12 is characteristic of both PV and PMF and that the resulting truncated forms of CXCL12, in addition to the reduced expression of CXCR4 by CD34(+) cells, lead to a profound mobilization of HSC/HPC in PMF. (c)2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20388788     DOI: 10.1158/0008-5472.CAN-09-3977

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  28 in total

1.  Processing of CXCL12 by different osteoblast-secreted cathepsins.

Authors:  Nicole D Staudt; Andreas Maurer; Bärbel Spring; Hubert Kalbacher; Wilhelm K Aicher; Gerd Klein
Journal:  Stem Cells Dev       Date:  2012-01-04       Impact factor: 3.272

Review 2.  Molecular mechanisms underlying adhesion and migration of hematopoietic stem cells.

Authors:  Aysegul Ocal Sahin; Miranda Buitenhuis
Journal:  Cell Adh Migr       Date:  2012 Jan-Feb       Impact factor: 3.405

Review 3.  The bone marrow stroma in hematological neoplasms--a guilty bystander.

Authors:  Claudio Tripodo; Sabina Sangaletti; Pier P Piccaluga; Sonam Prakash; Giovanni Franco; Ivan Borrello; Attilio Orazi; Mario P Colombo; Stefano A Pileri
Journal:  Nat Rev Clin Oncol       Date:  2011-03-29       Impact factor: 66.675

4.  Splenic extramedullary hematopoietic proliferation in Philadelphia chromosome-negative myeloproliferative neoplasms: heterogeneous morphology and cytological composition.

Authors:  Sonam Prakash; Ronald Hoffman; Sharon Barouk; Y Lynn Wang; Daniel M Knowles; Attilio Orazi
Journal:  Mod Pathol       Date:  2012-03-02       Impact factor: 7.842

5.  Stromal-derived factor-1 deficiency in the bone marrow of acute myeloid leukemia.

Authors:  Jian Ge; Ruiqin Hou; Quanhua Liu; Rongjia Zhu; Kaiyan Liu
Journal:  Int J Hematol       Date:  2011-05-24       Impact factor: 2.490

6.  Dipeptidylpeptidase 4 negatively regulates colony-stimulating factor activity and stress hematopoiesis.

Authors:  Hal E Broxmeyer; Jonathan Hoggatt; Heather A O'Leary; Charlie Mantel; Brahmananda R Chitteti; Scott Cooper; Steven Messina-Graham; Giao Hangoc; Sherif Farag; Sara L Rohrabaugh; Xuan Ou; Jennifer Speth; Louis M Pelus; Edward F Srour; Timothy B Campbell
Journal:  Nat Med       Date:  2012-11-18       Impact factor: 53.440

Review 7.  Rational therapeutic options for patients with myeloproliferative neoplasms.

Authors:  Ronald Hoffman
Journal:  Trans Am Clin Climatol Assoc       Date:  2011

8.  Release of matrix metalloproteinase-8 during physiological trafficking and induced mobilization of human hematopoietic stem cells.

Authors:  Carolin Steinl; Mike Essl; Thomas D Schreiber; Konstanze Geiger; Lea Prokop; Stefan Stevanović; Oliver Pötz; Harald Abele; Johannes T Wessels; Wilhelm K Aicher; Gerd Klein
Journal:  Stem Cells Dev       Date:  2013-02-12       Impact factor: 3.272

Review 9.  Novel targets to cure primary myelofibrosis from studies on Gata1low mice.

Authors:  Maria Zingariello; Fabrizio Martelli; Paola Verachi; Claudio Bardelli; Francesca Gobbo; Maria Mazzarini; Anna Rita Migliaccio
Journal:  IUBMB Life       Date:  2019-11-21       Impact factor: 3.885

Review 10.  Myeloproliferative neoplasm animal models.

Authors:  Ann Mullally; Steven W Lane; Kristina Brumme; Benjamin L Ebert
Journal:  Hematol Oncol Clin North Am       Date:  2012-08-21       Impact factor: 3.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.